---
figid: PMC5742578__fimmu-08-01897-g001
figtitle: Structure and function of ARNAX
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5742578
filename: fimmu-08-01897-g001.jpg
figlink: /pmc/articles/PMC5742578/figure/F1/
number: F1
caption: Structure and function of ARNAX. (A) Structure and signaling pathway of ARNAX.
  ARNAX activates endosomal toll-like receptor 3 (TLR3), but not cytoplasmic MDA5/RIG-I.
  The TLR3–TICAM-1–IRF3–IFN-β signaling axis is indispensable in dendritic cells (DCs)
  for ARNAX-mediated cytotoxic T lymphocyte (CTL) induction. (B) ARNAX therapy enhances
  antitumor responses in conjunction with PD-1/PD-L1 blockade. Tumors are self-originating
  and essentially lack adjuvant. In the absence of adjuvant, DCs remain immature state
  (immature DC) and fail to induce tumor-associated antigen (TAA)-specific CTLs (upper
  left panel). ARNAX activates TLR3 in DCs to induce maturation and cross-priming
  of TAA-specific CTLs in lymphoid tissues (priming phase) (lower left panel). PD-1/PD-L1
  blockade potentiates ARNAX-mediated CTL induction in the priming phase and reinvigorates
  tumor infiltrating CTLs in the effector phase (right panel).
papertitle: Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.
reftext: Misako Matsumoto, et al. Front Immunol. 2017;8:1897.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8716621
figid_alias: PMC5742578__F1
figtype: Figure
redirect_from: /figures/PMC5742578__F1
ndex: fe18e3fd-df16-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5742578__fimmu-08-01897-g001.html
  '@type': Dataset
  description: Structure and function of ARNAX. (A) Structure and signaling pathway
    of ARNAX. ARNAX activates endosomal toll-like receptor 3 (TLR3), but not cytoplasmic
    MDA5/RIG-I. The TLR3–TICAM-1–IRF3–IFN-β signaling axis is indispensable in dendritic
    cells (DCs) for ARNAX-mediated cytotoxic T lymphocyte (CTL) induction. (B) ARNAX
    therapy enhances antitumor responses in conjunction with PD-1/PD-L1 blockade.
    Tumors are self-originating and essentially lack adjuvant. In the absence of adjuvant,
    DCs remain immature state (immature DC) and fail to induce tumor-associated antigen
    (TAA)-specific CTLs (upper left panel). ARNAX activates TLR3 in DCs to induce
    maturation and cross-priming of TAA-specific CTLs in lymphoid tissues (priming
    phase) (lower left panel). PD-1/PD-L1 blockade potentiates ARNAX-mediated CTL
    induction in the priming phase and reinvigorates tumor infiltrating CTLs in the
    effector phase (right panel).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - mv
  - as
  - ctl
  - cutlet
  - dc
  - ab
  - Appl
  - GYPC
  - IFNB1
  - IRF3
  - TLR3
  - TICAM1
  - IFIH1
  - RIGI
  - MAVS
  - IFNAR1
  - IFNAR2
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - CD274
  - APP
  - SUCLA2
---
